August 26, 2025Frontiers in OncologyOpen Access

Real-world cardiovascular risks of ibrutinib in chronic lymphocytic leukemia: a retrospective study

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective study highlights cardiotoxicity in CLL patients treated with ibrutinib, suggesting close cardiovascular monitoring.

Cardiotoxicity occurred in 29.1% of patients, leading to treatment discontinuation in many cases due to serious cardiovascular events.
Patients with prior cardiovascular disease had a threefold increased risk of developing cardiotoxicity (HR=2.850; p=0.031).
The study analyzed 79 CLL patients to identify the incidence of cardiotoxicity and associated risk factors for developing complications.
Strong associations were found between hypertension and worsened cardiovascular outcomes during ibrutinib therapy, indicating a need for vigilant monitoring.

Ivanovic et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark